Celestia Higano
Hematology & Oncology · Seattle, WANPI 1972689727
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $131,921 of the $164,372 with a category attached, or 80.3%. 20 manufacturers reported payments, led by Astrazeneca UK Limited at 33.4% of the total. Reporting peaked in 2019 at $81,757 and has fallen 55.0% since, to $36,775 in 2025. Among hematology & oncology clinicians in WA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 103 payments — averaging $1595.84 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Astrazeneca UK Limited$55K
- Bayer$26K
- Astellas Pharma Inc$11K
- Ferring Pharmaceuticals Inc.$11K
- Pfizer$9K
- Merck$8K
- plus $44K from 14 others
Across 103 payments — averaging $14,175 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Pfizer$644K
- Astrazeneca UK Limited$461K
- Clovis Oncology, Inc.$146K
- Bayer$56K
- Aptevo Therapeutics Inc$52K
- F. Hoffmann-la Roche AG$49K
- plus $53K from 4 others
What the payments were for
- Consulting fees$131,92180%
- Speaking & faculty fees$14,4309%
- Travel & lodging$16,12910%
- Food & beverage$1,8411%
- Education$500%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Astrazeneca UK Limited | 30 | $54,900 |
| Bayer | 10 | $26,466 |
| Astellas Pharma Inc | 6 | $11,412 |
| Ferring Pharmaceuticals Inc. | 10 | $10,974 |
| Pfizer | 8 | $8,680 |
| Merck | 10 | $8,160 |
| Astrazeneca AB | 3 | $7,300 |
| Astellas Pharma US Inc | 3 | $6,318 |
| Advanced Accelerator Applications | 3 | $5,728 |
| Blue Earth Diagnostics | 4 | $5,213 |
| Janssen Scientific Affairs, LLC | 5 | $4,502 |
| Eli Lilly | 1 | $3,600 |
| Genentech, Inc. | 1 | $2,640 |
| Tolmar Pharmaceuticals, Inc. | 1 | $2,600 |
| AstraZeneca | 1 | $2,398 |
| Clovis Oncology, Inc. | 2 | $1,550 |
| Dendreon Pharmaceuticals LLC | 1 | $1,500 |
| Progenics Pharmaceuticals, Inc. | 2 | $239 |
| Myovant Sciences Inc. | 1 | $110 |
| Menarini Silicon Biosystems, Inc. | 1 | $84 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$164,372 in reported general payments places this provider in the 95th percentile of 349 hematology & oncology providers in Washington.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OrgovyxRelugolix | 12 | $31,982 |
Paid to pharmacies, not to this prescriber.
Other hematology & oncology in Seattle
- John PesandoSeattle$15.7M
- Jill JohnsenSeattle$991K
- Fengting YanSeattle$841K
- John PagelSeattle$725K
- Lawrence FongSeattle$546K
- Langdon MillerSeattle$457K
- Mazyar ShadmanSeattle$226K
- Catherine LeeSeattle$199K
- Ryan CassadaySeattle$151K
- Rebecca Kruse-JarresSeattle$140K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.